JIA-HORNG KAO2021-09-042021-09-0420090028-4793https://www.scopus.com/inward/record.uri?eid=2-s2.0-68049142597&partnerID=40&md5=a49f4cbecce68e15449d28e58fe84d13https://scholars.lib.ntu.edu.tw/handle/123456789/582112[SDGs]SDG3peginterferon; ribavirin; telaprevir; add on therapy; antiviral therapy; Asian; clinical trial; drug efficacy; drug response; European American; genotype; hepatitis C; Hepatitis C virus; human; letter; priority journal; virology; Antiviral Agents; Asian Continental Ancestry Group; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Alfa-2a; Oligopeptides; Polyethylene Glycols; Ribavirinletter196450832-s2.0-68049142597